BioNexus Gene Lab Corp. Enters Material Definitive Agreement
Ticker: BGLC · Form: 8-K · Filed: Aug 26, 2024 · CIK: 1737523
| Field | Detail |
|---|---|
| Company | Bionexus Gene Lab CORP (BGLC) |
| Form Type | 8-K |
| Filed Date | Aug 26, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, corporate-event
TL;DR
BioNexus Gene Lab Corp. signed a big deal, filing an 8-K on 8/26/24.
AI Summary
BioNexus Gene Lab Corp. announced on August 26, 2024, that it has entered into a material definitive agreement. The company, incorporated in Wyoming with its principal executive offices in Kuala Lumpur, is involved in medical laboratories.
Why It Matters
This filing indicates a significant new contract or partnership for BioNexus Gene Lab Corp., which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities, the specifics of which are not detailed in this initial filing.
Key Players & Entities
- BioNexus Gene Lab Corp. (company) — Registrant
- August 26, 2024 (date) — Date of earliest event reported
- Wyoming (jurisdiction) — State of incorporation
- Kuala Lumpur (location) — Business and mail address city
FAQ
What is the nature of the material definitive agreement entered into by BioNexus Gene Lab Corp.?
The filing does not specify the details of the material definitive agreement, only that one has been entered into as of August 26, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 26, 2024.
In which state is BioNexus Gene Lab Corp. incorporated?
BioNexus Gene Lab Corp. is incorporated in Wyoming.
Where are the principal executive offices of BioNexus Gene Lab Corp. located?
The principal executive offices of BioNexus Gene Lab Corp. are located in Kuala Lumpur.
What is the SIC code for BioNexus Gene Lab Corp.?
The Standard Industrial Classification (SIC) code for BioNexus Gene Lab Corp. is 8071, which corresponds to SERVICES-MEDICAL LABORATORIES.
Filing Stats: 687 words · 3 min read · ~2 pages · Grade level 11.8 · Accepted 2024-08-26 12:05:24
Filing Documents
- bglc_8k.htm (8-K) — 29KB
- bglc_ex101.htm (EX-10.1) — 272KB
- bglc_ex991.htm (EX-99.1) — 5KB
- bglc_ex101img9.jpg (GRAPHIC) — 25KB
- bglc_ex101img8.jpg (GRAPHIC) — 1KB
- bglc_ex101img10.jpg (GRAPHIC) — 15KB
- 0001477932-24-005269.txt ( ) — 531KB
- bglc-20240826.xsd (EX-101.SCH) — 6KB
- bglc-20240826_lab.xml (EX-101.LAB) — 15KB
- bglc-20240826_cal.xml (EX-101.CAL) — 1KB
- bglc-20240826_pre.xml (EX-101.PRE) — 9KB
- bglc-20240826_def.xml (EX-101.DEF) — 2KB
- bglc_8k_htm.xml (XML) — 4KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement On August 23, 2024, BioNexus Gene Lab Corp. ("BGLC" or the "Company"), through its wholly-owned subsidiary, MRNA Scientific Sdn Bhd, finalized its strategic investment in Ascension Innovation Sdn Bhd ("AISB"), a Malaysian-based healthcare technology company. The investment, totaling RM 1 million (approximately USD 228k), was made to acquire a significant equity stake in AISB. The funds were used to subscribe to 10,758 units of Ordinary Shares in AISB. This strategic investment is aimed at accelerating AISB's development and deployment of its AI-driven healthcare solutions, particularly through its aiCMS platform, which integrates predictive analytics and generative AI tools for enhanced patient care. The full terms and conditions of the investment are set forth in the Shareholders Agreement dated August 23, 2024, between MRNA Scientific Sdn Bhd and Ascension Innovation Sdn Bhd, among other parties. This agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On August 26, 2024, the Company issued a press release announcing the closing of its RM 1 million (Approx. USD 228k) investment in Ascension Innovation Sdn Bhd. The press release highlights the strategic importance of the investment in expanding BGLC's presence in the digital health sector and enhancing its genomic screening services through collaboration with AISB. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
01 Other Events
Item 8.01 Other Events The Company believes that this investment will significantly enhance its ability to expand the market reach of its blood-based genomic screening services by integrating them into AISB's digital health platforms. The collaboration is expected to create new synergies between BGLC's expertise in genomic diagnostics and AISB's innovative AI-driven healthcare solutions, ultimately benefiting healthcare providers and patients. 2
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit Description 10.1 Shareholders Agreement and Term Sheet dated August 23, 2024 99.1 Press Release Dated August 26, 2024 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioNexus Gene Lab Corp. Date: August 26, 2024 By: /s/ Su-Leng Tan Lee Name: Su-Leng Tan Lee Title: Chief Executive Officer 4